International Journal of Hematology and Oncology
2023, Vol 33, Num 4 (Special Issue) Page(s): 001-012
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Management of Invasive Fungal Infections: What to Consider in Empirical Treatment?
Fatih DEMIRKAN1, Guray SAYDAM2, Bilgin ARDA3, M. Ali OZCAN1
1Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, TURKEY
2Ege University Faculty of Medicine, Department of Hematology, Izmir, TURKEY
3Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Izmir, TURKEY
Keywords: Invasive fungal infection, Empirical antifungal therapy
Invasive fungal infections (IFI) are a major cause of morbidity and mortality in immunocompromised patients. Candida and Aspergillus are the most common fungi that lead to IFI. While invasive Candida infections are most commonly seen in patients in intensive care units (ICUs) and very low birth weight infants, aspergillosis is most frequent in immunocompromised patients, especially in patients with hematological malignancies and in those undergoing hematopoietic stem cell transplantation (HSCT). Empirical treatment should be considered in all high-risk patients with hematological malignancies suspected of having IFIs.
Fatih DEMIRKAN1, Guray SAYDAM2, Bilgin ARDA3, M. Ali OZCAN1
1Dokuz Eylul University Faculty of Medicine, Department of Hematology, Izmir, TURKEY
2Ege University Faculty of Medicine, Department of Hematology, Izmir, TURKEY
3Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Izmir, TURKEY
Keywords: Invasive fungal infection, Empirical antifungal therapy
Invasive fungal infections (IFI) are a major cause of morbidity and mortality in immunocompromised patients. Candida and Aspergillus are the most common fungi that lead to IFI. While invasive Candida infections are most commonly seen in patients in intensive care units (ICUs) and very low birth weight infants, aspergillosis is most frequent in immunocompromised patients, especially in patients with hematological malignancies and in those undergoing hematopoietic stem cell transplantation (HSCT). Empirical treatment should be considered in all high-risk patients with hematological malignancies suspected of having IFIs.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |